{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-241345","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2023-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.799786+00:00","generated_at":"2026-06-10T09:15:29.540085+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"ARS Pharma updates corporate presentation for Q4 2023 investor meetings","bullets":["Company posted updated corporate presentation on its website and furnished as Exhibit 99.1.","Presentation covers pipeline, clinical data, and commercial strategy for neffy (epinephrine nasal spray).","No financial updates or forward guidance included in the filing or presentation summary provided.","Presentation is furnished under Regulation FD; not incorporated by reference into SEC filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-241345","json":"https://secwatch.observer/filing/0001193125-23-241345.json","markdown":"https://secwatch.observer/filing/0001193125-23-241345.md","text":"https://secwatch.observer/filing/0001193125-23-241345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523241345/0001193125-23-241345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312523241345/d557739d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:15:29.540085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}